UNI-BIO SCIENCE GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.079 HKD | 0.00% |
|
-7.06% | +9.72% |
| Mar. 27 | Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 14 | Uni-Bio Science's Profit to Climb in 2023 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 440M 56.32M | Sales 2023 | 485M 62M | Capitalization | 452M 57.82M |
|---|---|---|---|---|---|
| Net income 2022 | 38M 4.86M | Net income 2023 | 70M 8.95M | EV / Sales 2022 | 0.85 x |
| Net cash position 2022 | 85.82M 10.98M | Net cash position 2023 | 85.56M 10.94M | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
11.9
x | P/E ratio 2023 |
6.49
x | Employees | 407 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.61% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -7.06% | ||
| Current month | -4.82% | ||
| 1 month | -10.23% | ||
| 3 months | -11.24% | ||
| 6 months | +64.58% | ||
| Current year | +9.72% |
1 week
0.08
0.09
1 month
0.080.10
Current year
0.070.11
1 year
0.040.11
3 years
0.040.12
5 years
0.040.23
10 years
0.040.30
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Gang Zhao
CEO | Chief Executive Officer | 64 | 14-03-31 |
Wei Tian
ADM | Chief Administrative Officer | 41 | - |
Jing Li
CTO | Chief Tech/Sci/R&D Officer | 45 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhi Gang Zhao
CEO | Chief Executive Officer | 64 | 14-03-31 |
Da Wei Chen
BRD | Director/Board Member | 54 | 17-01-12 |
Kingsley Leung
CHM | Chairman | 37 | 13-07-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 0.079 | 0.00% | 8 240 000 |
| 24-05-07 | 0.079 | -1.25% | 16,600,000 |
| 24-05-06 | 0.08 | -4.76% | 3,394,400 |
| 24-05-03 | 0.084 | -1.18% | 34,135,790 |
| 24-05-02 | 0.085 | +2.41% | 1,100,000 |
Delayed Quote Hong Kong S.E., May 08, 2024 at 04:08 am EDT
More quotes
Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-29
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.72% | 62.26M | |
| -2.35% | 89.33B | |
| +3.29% | 41.19B | |
| -15.40% | 31.87B | |
| +52.47% | 24.52B | |
| -14.35% | 15.68B | |
| -39.65% | 12.23B | |
| -6.52% | 12.34B | |
| -13.41% | 12.21B | |
| +5.32% | 8.83B |
- Stock Market
- Equities
- 690 Stock